• Thermo Fisher completed the sale of its microbiology business to private equity firm Astorg for about $1.075 billion.
• Consideration comprised cash, backed by a $50 million seller note.
• The unit provides antimicrobial susceptibility testing, culture media for clinical, pharmaceutical, food safety testing.
• The business generated $645 million of revenue in 2025 within Thermo Fisher’s Specialty Diagnostics segment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812171039) on August 12, 2026, and is solely responsible for the information contained therein.